Beam’s Breakthrough: Revolutionizing Genetic Medicine?
Beam Therapeutics Inc., a leading biotechnology company specializing in precision genetic medicines through base editing, has recently made a significant announcement. In August, the company initiated treatment for its first patient with BEAM-201, a quadruplex-edited allogeneic CAR-T cell investigational therapy. This therapy is currently under evaluation in a Phase 1/2 clinical trial aimed at treating […]
Cell and Gene Therapy Companies Leverage GenScript’s cGMP sgRNA Capability to Accelerate Speed to Market
PISCATAWAY, N.J., Dec. 15, 2022 /PRNewswire/ — GenScript USA Inc., the world’s leading life-science service provider, recently expanded its global current Good Manufacturing Practices (cGMP) single-guide RNA (sgRNA) manufacturing capabilities to meet the growing demand for cell and gene therapies. GenScript’s 400,000 square-foot cGMP facility enables next-generation gene and cell therapy R&D programs to advance IND filings and clinical trials. “We are […]
The future of ALL treatment: moving away from stem cell transplantation
Nicholas Short, MD, University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into future treatment approaches in acute lymphoblastic leukemia (ALL), highlighting the growing role of inotuzumab ozogamicin, blinatumomab, and CAR-T cells. Dr Short further explains the importance of moving away from stem cell transplantation and bringing novel agents and CAR-T therapy […]